GHRH analogs (clinic-compounded class discussion)

GHRH analogs are peptides discussed for stimulating the body's own growth-hormone release. This card compares tesamorelin, sermorelin and two different CJC forms, rather than one interchangeable clinic blend. People seek waist changes, better sleep and recovery; reports include little benefit, insomnia and fluid retention.

One pathway, different peptides. GHRH means growth-hormone-releasing hormone: a signal to the pituitary gland. GH then influences IGF-1, a downstream growth signal. Tesamorelin is a modified longer GHRH peptide; sermorelin and Mod GRF are shorter analogs. Ipamorelin acts at a different receptor and is a stack partner, not another GHRH analog. DailyMed: EGRIFTA SV prescribing information (Official context · Accessed 2026-09-30)

DAC changes the comparison. Mod GRF 1–29 is often sold as CJC without DAC. CJC with DAC has an albumin-binding modification that prolongs exposure. Branded tesamorelin, compounded vials and premixed injections are different products. Oral or nasal marketing does not inherit injected tesamorelin evidence. Teichman et al.: long-acting CJC-1295 in healthy adults (Official context · Accessed 2026-09-30)

Source context — DailyMed: EGRIFTA SV prescribing information: Named branded formulation in defined populations. Does not establish compounded blend PK or healthy-athlete efficacy. Instructions for mixing not reproduced.

Source context — Teichman et al.: long-acting CJC-1295 in healthy adults: Abstract inspected, not full paper. Short hormonal/PK study, not proof of sleep improvement, fat loss or long-term safety; not Mod GRF without DAC.

A smaller midsection. Tesamorelin discussions emphasize visceral fat around organs. Pinchable lower-belly fat, waist size and scale weight are different outcomes. CJC and sermorelin are also discussed for retaining muscle during a cut, but a shared pathway does not establish equal fat-loss results. Tesamorelin for belly fat with about five weeks until vacation? (Community discussion · Accessed 2026-09-30)

Tesamorelin accounts disagree even after weeks. The vacation discussion includes little lower-belly change at five weeks, claimed results at eight weeks with ipamorelin, a two-inch claim around week 14, and only four pounds lost over eight months. These are different endpoints and co-exposures, not an averaged onset window. Tesamorelin for belly fat with about five weeks until vacation? (Community discussion · Accessed 2026-09-30)

Sleep, recovery and steadier energy. Sermorelin and CJC plus ipamorelin accounts describe deeper sleep, vivid dreams or easier recovery. Other posters report no sleep improvement or disrupted sleep. Better-feeling mornings and anti-aging claims do not establish rejuvenation or new muscle tissue. My Sermorelin Experience (Community discussion · Accessed 2026-09-30)

Feeling better and sleeping worse both appear. In the sermorelin log, a reply described bedtime use ruining sleep and switching to morning. Another liked overall wellbeing but reported achiness attributed to water retention. The author was tapering enclomiphene; a favorable body-composition reply also disclosed semaglutide and hormone treatment. My Sermorelin Experience (Community discussion · Accessed 2026-09-30)

Labs and higher amounts do not settle success. A MESO-Rx poster claimed an IGF increase at 0.5 mg daily; another reported bloat at 1.5 mg. Neither verifies potency. An ExcelMale poster treated flushing as a cue without GH tests. Original clinic talk mentions IGF-1/glucose checks around weeks 2–4, but labs do not measure fat loss. Why use growth hormone releasing peptides instead of HGH? — page 4 (Community discussion · Accessed 2026-09-30) · Began an experiment with ipamorelin and CJC-1295 without DAC — page 2 (Community discussion · Accessed 2026-09-30)

Source context — Tesamorelin for belly fat with about five weeks until vacation?: Visible extraction leaves More replies unopened. Products, waist and lab values unverified; no unit for the claimed IGF increase. Diet, retatrutide and ipamorelin confound results. Relative dates not converted.

Source context — My Sermorelin Experience: OP's 0.3 and 0.45 have no units: excluded from dose amounts. Enclomiphene taper, changing diet, hormones and other peptides prevent isolated attribution. Replies not all expanded.

Source context — Why use growth hormone releasing peptides instead of HGH? — page 4: Only initially returned posts read; later page access failed. Route not specified in these reports. Lab attachments not inspected; do not infer units or confirm IGF changes. Cost/potency comparisons are personal opinions.

Source context — Began an experiment with ipamorelin and CJC-1295 without DAC — page 2: Older anecdotes; route beneath skin not explicitly stated in these selected reports. No GH testing; flushing interpreted by one poster as effect. Surrounding high-dose guide and mixing recipes not adopted.

Tesamorelin: 1–2 mg SubQ daily in the community record. SubQ means beneath the skin; 1 mg equals 1,000 mcg. The 2 mg figure repeats older trials. Starting at 1 mg for 1–2 weeks before 2 mg, or splitting daily totals, circulates for cost/tolerance. Bedtime stack examples pair 1–2 mg tesamorelin with 200–300 mcg ipamorelin, sometimes five or six nights weekly. These are unvalidated reports, not instructions.

Sermorelin: 100–500 mcg SubQ nightly in clinic/forum charts. The recurring narrower band is 200–300 mcg. An inspected sleep discussion reports 300 mcg before bed. These are adult wellness reports, with five-night and every-night calendars, not amounts transferable to tesamorelin. Sermorelin Sleep (Community discussion · Accessed 2026-09-30)

Short CJC: 100–300 mcg per SubQ injection, one to three times daily in charts. One older forum account used 100 mcg CJC without DAC plus 100 mcg ipamorelin nightly. Other charts pair 100 mcg CJC with 200–300 mcg ipamorelin. Each ingredient amount matters; a blend total is not the amount of each peptide. Began an experiment with ipamorelin and CJC-1295 without DAC — page 2 (Community discussion · Accessed 2026-09-30)

CJC with DAC: separate, less-frequent amounts. Preserved charts discuss 1–2 mg SubQ once or twice weekly. A sleep-thread respondent instead described injected 500 mcg every four days, with route unspecified, alongside ipamorelin and DSIP. Neither schedule establishes a best dose. Sermorelin Sleep (Community discussion · Accessed 2026-09-30)

Source context — Sermorelin Sleep: Self-reports, not sleep-lab evidence. Injection discussion does not specify beneath-skin route for every individual. Several replies are hidden/deleted. Co-use includes DSIP.

Source context — Began an experiment with ipamorelin and CJC-1295 without DAC — page 2: Older anecdotes; route beneath skin not explicitly stated in these selected reports. No GH testing; flushing interpreted by one poster as effect. Surrounding high-dose guide and mixing recipes not adopted.

Sleep may change before appearance. One sermorelin poster reported improved sleep in the first week; another felt different within two to three weeks and described visible composition change only after months. Brief flushing or injection sting in the original accounts is an early sensation, not proof of effectiveness. Sermorelin Sleep (Community discussion · Accessed 2026-09-30) · My Sermorelin Experience (Community discussion · Accessed 2026-09-30)

Tesamorelin accounts disagree even after weeks. The vacation discussion includes little lower-belly change at five weeks, claimed results at eight weeks with ipamorelin, a two-inch claim around week 14, and only four pounds lost over eight months. These are different endpoints and co-exposures, not an averaged onset window. Tesamorelin for belly fat with about five weeks until vacation? (Community discussion · Accessed 2026-09-30)

No dependable single-injection benefit window. Most accounts concern repeated use. A sermorelin author described steadier energy but noticed differences during week-long supply interruptions. Tesamorelin replies disagree about water settling after stopping; confidently posted day counts are not follow-up measurements or a guaranteed recovery timeline. My Sermorelin Experience (Community discussion · Accessed 2026-09-30) · Tesamorelin for belly fat with about five weeks until vacation? (Community discussion · Accessed 2026-09-30)

Community charts circulate minutes for short forms and days for DAC. A vendor-linked Reddit chart lists tesamorelin 26 minutes, sermorelin 10–20 minutes, CJC without DAC 30 minutes, and CJC with DAC 6–8 days. The DAC number reflects formal human PK literature, not a community measurement. The other chart values lack formulation-specific sourcing. CJC no DAC, CJC with DAC, sermorelin and tesamorelin comparison (Community guide · Accessed 2026-09-30)

There is no measured class-wide or blend half-life. Older short-CJC discussion spans about 25–30 minutes to under an hour. These are circulated estimates. Half-life describes loss of measured peptide, not sleep duration or how quickly waist fat changes; branded measurements are separately identified below.

SV and WR are different formulations. SV labeling specifies 1.4 mg SubQ daily and an 8-minute mean single-dose half-life; WR specifies 1.28 mg SubQ daily and 11 minutes, both measured in healthy subjects. WR's weekly vial preparation still supplies daily injections. These do not measure a compounded blend. DailyMed: EGRIFTA SV prescribing information (Official context · Accessed 2026-09-30) · DailyMed: EGRIFTA WR prescribing information (Official context · Accessed 2026-09-30)

DAC's longer exposure was measured formally. A healthy-adult SC CJC-1295 study estimated a 5.8–8.1-day half-life, with GH elevated at least six days and IGF-I nine to eleven days after one injection. This is hormonal/PK evidence, not a measured duration of better sleep or fat loss. Teichman et al.: long-acting CJC-1295 in healthy adults (Official context · Accessed 2026-09-30)

Source context — Sermorelin Sleep: Self-reports, not sleep-lab evidence. Injection discussion does not specify beneath-skin route for every individual. Several replies are hidden/deleted. Co-use includes DSIP.

Source context — My Sermorelin Experience: OP's 0.3 and 0.45 have no units: excluded from dose amounts. Enclomiphene taper, changing diet, hormones and other peptides prevent isolated attribution. Replies not all expanded.

Source context — Tesamorelin for belly fat with about five weeks until vacation?: Visible extraction leaves More replies unopened. Products, waist and lab values unverified; no unit for the claimed IGF increase. Diet, retatrutide and ipamorelin confound results. Relative dates not converted.

Source context — CJC no DAC, CJC with DAC, sermorelin and tesamorelin comparison: Vendor-named author and vendor promotion in thread. Circulated values, not original human measurements. The DAC figure resembles primary trial PK; the tesamorelin and sermorelin figures lack product/route-specific citations.

Source context — DailyMed: EGRIFTA SV prescribing information: Named branded formulation in defined populations. Does not establish compounded blend PK or healthy-athlete efficacy. Instructions for mixing not reproduced.

Source context — DailyMed: EGRIFTA WR prescribing information: WR is a specific formulation; multi-dose vial preparation does not mean weekly injection. No compounded-product equivalence can be inferred.

Source context — Teichman et al.: long-acting CJC-1295 in healthy adults: Abstract inspected, not full paper. Short hormonal/PK study, not proof of sleep improvement, fat loss or long-term safety; not Mod GRF without DAC.

Community courses vary by member. The original record describes tesamorelin aesthetic blocks of 8–16 weeks or ongoing use, sermorelin courses of 3–6 months, and CJC plus ipamorelin blocks of 8–12 weeks with roughly four weeks off. Some continue longer; no safe or optimal course is established.

Five days on, two off is a scheduling preference. Daily use, six days on/one off and three-on/one-off templates also appear. Cost, convenience, swelling, glucose or IGF-1 concerns motivate breaks. Claims about receptor rest and a required post-cycle therapy lack a validated class-wide rule.

GHRH + GHRP (class default): Tesamorelin or CJC or sermorelin + Ipamorelin (or older GHRP-2/6) = top dual-pathway “GH pulse” stack — confounds credit and can amplify water/joint/IGF-1 sides. [community]

Tesamorelin: 1–2 mg SubQ daily in the community record. SubQ means beneath the skin; 1 mg equals 1,000 mcg. The 2 mg figure repeats older trials. Starting at 1 mg for 1–2 weeks before 2 mg, or splitting daily totals, circulates for cost/tolerance. Bedtime stack examples pair 1–2 mg tesamorelin with 200–300 mcg ipamorelin, sometimes five or six nights weekly. These are unvalidated reports, not instructions.

Short CJC: 100–300 mcg per SubQ injection, one to three times daily in charts. One older forum account used 100 mcg CJC without DAC plus 100 mcg ipamorelin nightly. Other charts pair 100 mcg CJC with 200–300 mcg ipamorelin. Each ingredient amount matters; a blend total is not the amount of each peptide. Began an experiment with ipamorelin and CJC-1295 without DAC — page 2 (Community discussion · Accessed 2026-09-30)

Blend labels and added peptides complicate the picture. Sermorelin plus ipamorelin charts include 250–300 mcg plus 200–300 mcg, or equal 100–200 mcg amounts of each. A vial labeled 5 mg CJC plus 5 mg ipamorelin contains two ingredients. Identity, potency, sterility and DAC mislabeling remain practical concerns.

A stack can improve sleep without identifying the helpful ingredient. The sleep-thread respondent liked CJC with DAC plus ipamorelin while also using DSIP, but noticed no benefit from a 100 mcg each sermorelin/ipamorelin blend. Changing ingredients and amounts prevents a clean head-to-head comparison. Sermorelin Sleep (Community discussion · Accessed 2026-09-30)

Cost and competing treatments shape the stories. Community notes position short CJC plus ipamorelin as a cheaper tesamorelin alternative, and contrast injections with oral MK-677 or injected HGH. GLP-1 drugs, diet, lifting, alcohol changes, MOTS-c and recovery-peptide stacks all muddy credit. Adding multiple GHRH members also adds overlap rather than proving extra benefit.

Avoid redundant HGH stack (common caution): Running GHRH analogs + high-dose exogenous HGH often called unnecessary same-axis overload with stacked edema/glucose/IGF-1 risk. [community]

GLP-1 / dual / triple agonist combinations: Semaglutide, tirzepatide or retatrutide appear alongside tesamorelin in weight and waist-change reports. These GLP-1-based agents and concurrent diet changes prevent attributing the outcome to tesamorelin alone. [community]

+ MOTS-c: Appears in metabolic “cheat sheet” stacks with reta + tesa; preclinical/community adjacency more than a joint RCT. [community]

Fat-loss adjacency: Talk next to AOD-9604 / Frag 176-191 or deficit training — attribution muddy. [community]

Recovery adjacency: Occasional BPC-157 / TB-500 co-talk when joint comfort is already an issue on GH-axis drugs — separate mechanisms. [community]

Source context — Began an experiment with ipamorelin and CJC-1295 without DAC — page 2: Older anecdotes; route beneath skin not explicitly stated in these selected reports. No GH testing; flushing interpreted by one poster as effect. Surrounding high-dose guide and mixing recipes not adopted.

Source context — Sermorelin Sleep: Self-reports, not sleep-lab evidence. Injection discussion does not specify beneath-skin route for every individual. Several replies are hidden/deleted. Co-use includes DSIP.

Growth-hormone effects can become unwanted effects. Tesamorelin labeling warns about high IGF-1, glucose intolerance/diabetes, swelling, joint discomfort and carpal-tunnel symptoms. Injection reactions and allergy also occur. Active malignancy, pregnancy and disrupted pituitary function are contraindications; stimulating endogenous GH does not ensure safety. DailyMed: EGRIFTA SV prescribing information (Official context · Accessed 2026-09-30)

Blend labels and added peptides complicate the picture. Sermorelin plus ipamorelin charts include 250–300 mcg plus 200–300 mcg, or equal 100–200 mcg amounts of each. A vial labeled 5 mg CJC plus 5 mg ipamorelin contains two ingredients. Identity, potency, sterility and DAC mislabeling remain practical concerns.

DAC changes the comparison. Mod GRF 1–29 is often sold as CJC without DAC. CJC with DAC has an albumin-binding modification that prolongs exposure. Branded tesamorelin, compounded vials and premixed injections are different products. Oral or nasal marketing does not inherit injected tesamorelin evidence. Teichman et al.: long-acting CJC-1295 in healthy adults (Official context · Accessed 2026-09-30)

SV and WR are different formulations. SV labeling specifies 1.4 mg SubQ daily and an 8-minute mean single-dose half-life; WR specifies 1.28 mg SubQ daily and 11 minutes, both measured in healthy subjects. WR's weekly vial preparation still supplies daily injections. These do not measure a compounded blend. DailyMed: EGRIFTA SV prescribing information (Official context · Accessed 2026-09-30) · DailyMed: EGRIFTA WR prescribing information (Official context · Accessed 2026-09-30)

Tested sport has a separate restriction. WADA's 2026 list prohibits these GHRH analogs at all times. Community half-life estimates do not establish a drug-test clearance window. WADA 2026 Prohibited List (Official context · Accessed 2026-09-30)

Source context — DailyMed: EGRIFTA SV prescribing information: Named branded formulation in defined populations. Does not establish compounded blend PK or healthy-athlete efficacy. Instructions for mixing not reproduced.

Source context — Teichman et al.: long-acting CJC-1295 in healthy adults: Abstract inspected, not full paper. Short hormonal/PK study, not proof of sleep improvement, fat loss or long-term safety; not Mod GRF without DAC.

Source context — DailyMed: EGRIFTA WR prescribing information: WR is a specific formulation; multi-dose vial preparation does not mean weekly injection. No compounded-product equivalence can be inferred.

Source context — WADA 2026 Prohibited List: Sport rules only; no detection-clearance interval or medical safety claim.